Genomically guided drug testing for osteosarcoma in patient-derived models
Official title: Genomically informed agent selection and testing in osteosarcoma patient-derived xenograft models
Funded at University of Tx Md Anderson Can Ctr · NIH-11537822 · Data updated 2026-11-12
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | July 10, 2015 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $202,500 |
| NIH project number | 3U01CA199221-11S1 |
| Project ID | NIH-11537822 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with osteosarcoma, especially those with tumors reflecting diverse genomic profiles, could eventually benefit from translated therapies.
✕Less likely to help
Patients whose tumors do not respond to the identified targets or agents may not experience benefit.
What this research studies
In this project, researchers profile osteosarcoma tumors to find molecular targets and then test new agents in patient-derived models to see which treatments work best. They use a robust platform and PDX models to capture tumor diversity and conduct high-throughput in vivo testing each year. The ultimate aim is to identify agents that could move into clinical trials for children and adolescents with bone cancer.
Why it matters
Potential benefit: If successful, the work could identify new, targeted therapies for osteosarcoma that may improve survival and reduce side effects for young patients.
How similar studies have gone: Previous efforts have shown that targeted approaches can work in osteosarcoma when genomic targets are properly matched to therapies.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Gorlick, Richard G. — University of Tx Md Anderson Can Ctr
- Study coordinator: Gorlick, Richard G.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
-
Canine osteosarcoma immunity boost from hyperactivated dendritic cells
A study tests a way to spark a strong anti-tumor immune response in dogs with bone cancer using highly activated immune cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.